List of insiders holdings for Apellis Pharmaceuticals Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
Morningside Venture Investments Ltd 10% Owner | 2022-02-14 16:05:11 | 12,806,342 0 | 12,806,342 | Form 13G |
Potentia Holdings LLC 10% Owner | 2018-02-07 18:59:55 | 3,826,601 0 | 3,826,601 | Form 13G |
Cormorant Asset Management LLC Chen Bihua Cormorant Global Healthcare GP LLC Cormorant Global Healthcare Master Fund LP 10% Owner | 2020-02-14 16:07:26 | 2,700,000 0 | 2,700,000 | Form 13G |
Cormorant Asset Management LLC Cormorant Global Healthcare Master Fund LP CORMORANT PRIVATE HEALTHCARE FUND I LP Chen Bihua 10% Owner | 2020-02-14 16:07:26 | 2,700,000 0 | 2,700,000 | Form 13G |
AJU IB Investment Co. Ltd. 10% Owner | 2017-11-13 16:29:47 | 0 2,292,062 | 2,292,062 | Form 4 |
Hillhouse Capital Management Ltd. 10% Owner | 2019-02-14 15:15:04 | 2,098,581 0 | 2,098,581 | Form 13G |
Francois Cedric Chief Executive Officer | 2025-01-30 12:03:08 | 415,695 1,539,422 | 1,955,117 | Form 4 |
venBio Global Strategic Fund II L.P. 10% Owner | 2019-02-14 08:50:47 | 1,790,102 0 | 1,790,102 | Form 13G |
Deschatelets Pascal Chief Scientific Officer | 2025-01-30 12:07:31 | 1,147,716 0 | 1,147,716 | Form 4 |
GELLERT MICHAEL E 10% Owner | 2017-11-13 16:25:54 | 943,989 0 | 943,989 | Form 4 |
Machiels Alec Director | 2025-01-03 16:23:44 | 388,227 411,950 | 800,177 | Form 4 |
Axon Steven Chief Business Officer | 2018-11-15 20:40:03 | 398,499 0 | 398,499 | Form 4 |
Dunlop A. Sinclair Director | 2025-01-03 16:17:32 | 169,592 100,000 | 269,592 | Form 4 |
Watson David O. General Counsel | 2025-01-30 12:20:07 | 144,299 80,136 | 224,435 | Form 4 |
Sullivan Timothy Eugene Chief Financial Officer | 2025-01-30 12:15:46 | 128,665 70,396 | 199,061 | Form 4 |
SCHEIBLER LUKAS Chief Research Officer | 2023-12-05 19:40:46 | 107,690 0 | 107,690 | Form 4 |
Grossi Federico Chief Medical Officer | 2023-01-09 19:02:36 | 94,884 0 | 94,884 | Form 4 |
Baumal Caroline Chief Medical Officer | 2025-01-21 15:54:49 | 93,301 0 | 93,301 | Form 4 |
Townsend Adam J. Chief Commercial Officer | 2025-01-30 12:18:22 | 84,050 0 | 84,050 | Form 4 |
DeLong Mark Jeffrey Chief Business & Strat Officer | 2025-02-12 13:59:21 | 83,945 0 | 83,945 | Form 4 |
Nicholson Nur Chief Technical Officer | 2025-01-30 12:13:56 | 83,664 0 | 83,664 | Form 4 |
Lewis Karen Chief People Officer | 2025-01-30 12:12:03 | 70,251 0 | 70,251 | Form 4 |
Eisele Jeffrey Chief Development Officer | 2025-01-30 12:10:43 | 55,312 0 | 55,312 | Form 4 |
Chopas James George VP/Chief Accounting Officer | 2025-01-23 15:19:41 | 48,138 0 | 48,138 | Form 4 |
Celona Lucia See Remarks | 2020-02-12 16:58:26 | 36,488 0 | 36,488 | Form 4 |
FONTEYNE PAUL R. Director | 2025-01-03 16:19:39 | 33,904 0 | 33,904 | Form 4 |
O'Brien Stephanie Monaghan Director | 2025-01-03 16:25:24 | 28,904 0 | 28,904 | Form 4 |
Chan Gerald Director | 2025-01-03 16:12:41 | 28,904 0 | 28,904 | Form 4 |
Walbert Keli Director | 2025-01-10 17:39:26 | 24,478 0 | 24,478 | Form 4 |
Lackner Thomas A. See Remarks | 2020-02-12 16:50:35 | 24,075 0 | 24,075 | Form 4 |
Brown Victoria L. Program Team Lead | 2023-01-24 16:57:32 | 23,556 0 | 23,556 | Form 4 |
Sadr Ahmad See Remarks | 2020-02-12 16:46:30 | 19,075 0 | 19,075 | Form 4 |
Perry Nicole D Vice President - Accounting | 2021-08-03 16:23:59 | 11,008 0 | 11,008 | Form 4 |